Clinical trials: Significant Prostate Cancer, open to volunteers
Prostate Cancer
Sequential Imaging of Suspicion of Prostate Cancer Reducing Overdiagnosis and Unnecessary Biopsy With Timely Diagnosis of Significant Cancer
The goal of this clinical trial is to evaluate the safety and effectiveness of a novel diagnostic strategy for prostate cancer, in which men with a moderate risk of prostate cancer are monitored using PSA and MRI instead of…
- Trial name
- SPROUT (NCT07180381)
- Testing
- PSA and MRI-monitoring
- Where
- 7 sites in Netherlands
- Volunteers
- 503 people
- Sponsor
- St. Antonius Hospital
Clinically Significant Prostate Cancer
Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer
The aim of the present study is to investigate a plasma exosome RNA signature to diagnose clinically significant prostate cancer.
- Trial name
- NCT07492927
- Where
- 10 sites in United States, China
- Volunteers
- 1,700 people
- Sponsor
- Xijing Hospital
Prostatic Neoplasm of Uncertain Behavior
Combining High-frequency Micro-ultrasound and Multiparametric MRI Target Biopsy for Detecting Prostate Cancer
Study Goal: The purpose of this clinical trial is to determine if combining high-frequency micro-ultrasound with multiparametric MRI biopsy and a systematic biopsy can better detect clinically significant prostate cancer compared…
- Trial name
- Biopsy29 (NCT06579911)
- Testing
- High-frequency micro-ultrasound target biopsy, conventional Multiparametric MRT target biopsy
- Where
- Austria
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Salzburger Landeskliniken
Significant Prostate Cancer
Decipher Lethal Prostate Cancer Biology - Urine Metabolomics
Through a better understanding of the biology of significant (lethal) prostate cancer, we hope to develop new markers/targets from urine metabolomics for more effective screening and prevention of significant prostate cancer.
- Trial name
- NCT03237702
- Testing
- Multi-Carotenoids
- Where
- Taiwan
- Volunteers
- 2,000 people
- Sponsor
- National Taiwan University Hospital
Prostate Cancer
Ipsilateral Versus Bilateral Systematic Biopsy Combined With MRI/Ultrasound Cognitive Fusion Targeted Biopsy for Prostate Cancer Diagnosis
Prostate biopsy usually combines magnetic resonance imaging/ultrasound (MRI/US) cognitive fusion targeted biopsy with systematic biopsy.
- Trial name
- IBIS-PC (NCT07795723)
- Testing
- MRI/US Cognitive Fusion Targeted Biopsy Plus Ipsilateral Systematic Biopsy, MRI/US Cognitive Fusion Targeted Biopsy Plus Bilateral Systematic Biopsy
- Where
- China
- Volunteers
- 454 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Prostate Cancer (Diagnosis), Prostate Cancer
INSIGHT-PCa: MRI- and PHI-Guided Risk-Adapted Strategy for Prostate Cancer Diagnosis
Prostate cancer diagnosis based on systematic or MRI-targeted biopsy is associated with substantial overdiagnosis and unnecessary invasive procedures.
- Trial name
- INSIGHT-PCa (NCT07398690)
- Testing
- Diagnostic Procedure
- Where
- South Korea
- Volunteers
- 1,432 people
- Sponsor
- In Gab Jeong, MD
Prostate Cancer
Artificial Intelligence Software (Prostate Intelligence) for Detecting Clinically Significant Prostate Cancer on MRI
The goal of this study is to learn how accurately an artificial intelligence (AI) software called Prostate Intelligence (Pi) detects clinically significant prostate cancer on prostate MRI in adults with a prostate gland who are…
- Trial name
- RADAR (NCT07875491)
- Testing
- AI-based prostate MRI analysis software
- Where
- Italy
- Volunteers
- 226 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lymphoma, Advanced Prostate Cancer
Whole Body MRI in Oncology
Multicenter, observational, prospective, study. All patients will be treated and monitored according to the local clinical practice.
- Conditions
- Lymphoma, Advanced Prostate Cancer, Advanced Breast Cancer, Monoclonal Gammopathy of Undetermined Significance
- Trial name
- ONCO-MRI (NCT06895291)
- Testing
- Whole Body-Magnetic Resonance Imaging (WB-MRI)
- Where
- 3 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Prostate
POSLUMA® (18F-rhPSMA-7.3) PET-CT for PIRADS 2/3 Lesions
The goal of this study to determine if using the (18)F-rhPSMA-7.3 PET-CT scan can improve the ability to spot serious prostate cancer in patients who have uncertain MRI results.
- Trial name
- NCT07220720
- Testing
- Flotufolastat F 18
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Florida
Treatment-naive Prostate Cancer, Suspected Prostate Cancer
Delayed PSMA PET/CT Imaging for Diagnosing Clinically Significant Prostate Cancer in Biopsy-Naïve Men With Suspected Prostate Cancer
Brief Summary This prospective, multicenter study evaluates whether delayed PSMA PET imaging improves diagnostic efficacy for detecting clinically significant prostate cancer (Gleason score ≥7) compared with standard imaging in…
- Conditions
- Treatment-naive Prostate Cancer, Suspected Prostate Cancer, Molecular Imaging
- Trial name
- DEPICT (NCT07531329)
- Testing
- [⁶⁸Ga]Ga-PSMA PET/CT with Delayed Pelvic PET-Only Acquisition
- Where
- 9 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Xijing Hospital
Prostate Cancer, Active Surveillance for Prostate Cancer
Micro-Ultrasound for Detecting Clinically Significant Prostate Cancer in Active Surveillance
Active surveillance is a common approach for men with low-risk or favorable intermediate-risk prostate cancer, aimed at avoiding or delaying treatment while closely monitoring the disease.
- Conditions
- Prostate Cancer, Active Surveillance for Prostate Cancer, Imaging Techniques
- Trial name
- MUS-AS (NCT07386171)
- Testing
- Micro-Ultrasound (mUS)
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Low Risk Prostate Cancer, Clinically Significant Prostate Cancer
Study of PSMA PET/CT Imaging to Help Select Men With Low-Risk Prostate Cancer for Active Surveillance
This is a multicenter, prospective diagnostic accuracy study evaluating the Istanbul PSMA PET/CT Criteria (IPPC) for selecting patients with biopsy-confirmed low-risk prostate cancer (ISUP Grade 1) for active surveillance (AS).
- Trial name
- I-SELECT (NCT07168616)
- Testing
- Ga-68 PSMA11 PET/CT
- Where
- 10 sites in Turkey (Türkiye)
- Volunteers
- 201 people
- Sponsor
- Istanbul University - Cerrahpasa
High-risk Prostate Cancer, PSMA PET
Serial PSMA PET for Therapy Monitoring in Clinically Significant Prostate Cancer
This prospective, multicenter study aims to evaluate the clinical utility of serial PSMA PET for therapy monitoring in patients with newly diagnosed clinically significant prostate cancer.
- Conditions
- High-risk Prostate Cancer, PSMA PET, Treatment Response, Therapy Monitoring
- Trial name
- PSMA-TM (NCT07553780)
- Where
- 9 sites in China
- Volunteers
- 110 people
- Sponsor
- Xijing Hospital
Clinical Suspicion of Prostate Cancer
Fully Hybrid 18F-PSMA PET/MRI as One-stop Approach for the Diagnosis of Clinically Significant Prostate Cancer.
This project aims to evaluate the role of fully hybrid PET/MRI with 18FPSMA and multiparametric MR imaging (mpMRI) as one-stop approach for the diagnosis of clinically significant prostate cancer (csPCa).
- Trial name
- RF2021-1237227 (NCT06305390)
- Testing
- PET/MRI
- Where
- Italy
- Volunteers
- 167 people
- Sponsor
- IRCCS San Raffaele
Prostate Cancer (Diagnosis), Prostatic Neoplasms
Real-time Fluorescence Microscopy for Intraoperative Assessment of Prostate Biopsy Cores (FLASH)
Current prostate cancer diagnosis relies on MRI-targeted biopsy combined with a 12-core systematic biopsy. The systematic component is a major driver of overdiagnosis of insignificant cancer and biopsy-related morbidity, and…
- Trial name
- FLASH (NCT07846592)
- Testing
- Ex vivo real-time fluorescence microscopy of prostate biopsy cores (EndoScell system, model MES-1000P)
- Volunteers
- 450 people
- Sponsor
- Shanghai East Hospital
Prostate Cancer
Multiparametric Magnetic Resonance Imaging (mpMRI) Versus Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) for Detecting Clinically Significant Prostate Cancer in Transition Zone Lesions /PRostate Imaging With MRI and PET in the Transition Zone (PRIME-TZ)
This prospective, single-center diagnostic accuracy study will compare mpMRI and PSMA-PET for the detection of clinically significant prostate cancer in patients with prostate imaging reporting and data System (PI-RADS) ≥4…
- Trial name
- PRIME-TZ (NCT07892378)
- Testing
- Multiparametric Magnetic Resonance Imaging (mpMRI), 18F-PSMA-1007 PET, Prostate Biopsy
- Where
- Argentina
- Volunteers
- 65 people
- Sponsor
- Sanatorio Privado San Geronimo
Prostate Cancer
Detecting Clinically Significant Prostate Cancer With Advanced MRI Protocols and Extensive Histopathology
In recent years, new and promising approaches have emerged in the field of MRI imaging of the prostate. These approaches usually aim to visualise the so-called "microstructures" of the tissue and are intended to offer greater…
- Trial name
- NCT07432360
- Where
- Brazil
- Volunteers
- 300 people
- Sponsor
- Virdx, Inc.
Atrial Fibrillation, Coronary Heart Disease
EMPOWER-1: A Multi-site Clinical Cohort Research Study to Reduce Health Inequality
Health inequality and genetic disparity are a significant issue in the United Kingdom (UK). This study focuses on diseases that are associated with significant morbidity and mortality in the UK, and specifically examines the…
- Conditions
- Atrial Fibrillation, Coronary Heart Disease, Cardiovascular Diseases, Heart Failure
- Trial name
- EMPOWER (NCT03987633)
- Where
- United Kingdom
- Volunteers
- 200,000 people, healthy volunteers welcome
- Sponsor
- Future Genetics Limited
Prostate Cancer
Non-significant Risk (NSR) Study of [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on RefleXion X1
To qualitatively determine the imaging performance of PET-CT imaging subsystem of the RefleXion X1 System Device in patients undergoing standard-of-care (SOC) [68Ga]-PSMA-11 PET-CT using Illuccix on the same day.
- Trial name
- NCT06353321
- Testing
- PET-CT imaging subsystem of the RefleXion X1 System Device
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Texas Southwestern Medical Center
Prostate Cancer
A Randomized Trial of Early Detection of Clinically Significant Prostate Cancer (ProScreen)
A population-based randomised trial of prostate cancer screening will be carried out. A total of approximately 117,200 men aged 50-63 in Helsinki and Tampere are randomised to intervention (screening) or control arm.
- Trial name
- ProScreen (NCT03423303)
- Testing
- Prostate cancer screening
- Where
- 2 sites in Finland
- Volunteers
- 17,400 people, healthy volunteers welcome
- Sponsor
- Tampere University